Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9456870 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL6870640 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL22305184 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL8762490 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL28371763 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL28002725 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL2847154 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL6868590 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL22483069 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1231975 | 0.77 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306253-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2020-10-01 | — | — | US | disclosed |
| US-20200247758-A1 | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306253-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | ATP5ME, ATP5F1A, ATP5MG | ALDH1A1 925/4885MAPK1 3035/4885L3MBTL1 3403/4885 |
| US-20200247758-A1 | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase | ATP5ME, ATP5MG, ATP5F1A | ALDH1A1 369/4885MAPK1 3128/4885L3MBTL1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.